Dr. Zvonic earned his Doctorate in Cell and Molecular Biology at Louisiana State University, in the laboratory of Dr. Jacqueline Stephens, studying adipose tissue functions in the context of metabolic disease development. Continuing on to a post-doctoral position in Dr. Jeffrey Gimble's lab at Pennington Biomedical Research Center, Dr. Zvonic contributed to the development of methodologies for the isolation and culture of human adipose stem cells (ASC) from several sources, and later utilized ASCs to develop a human in vitro model for circadian biology studies.
He then joined Dr. Darwin Prockop's group at Tulane University, where he directed the technology transfer and development of bone marrow-derived MSC manufacturing and analytical methods in the in-house GMP production facility. In 2009, Dr. Zvonic joined PCT, where he focused on client engagement and technology transfer into PCT, giving him a comprehensive understanding of cell therapy development, manufacturing and commercialization requirements and strategies.
In 2014, he joined Novartis Cell and Gene Therapy Unit, where he focused on the development and commercialization of Novartis C/GT pipeline products. In 2016 Dr. Zvonic returned to PCT, with a focus on driving the growth and development of PCT's clinical and commercial manufacturing business lines.